Investors

News Releases

Date Title  
Toggle Summary Aralez Pharmaceuticals to Seek Court Approval of Previously Announced "Stalking Horse" Transactions for Substantially All Assets
MISSISSAUGA, ON, Nov. 29, 2018 /CNW/ - Aralez Pharmaceuticals Inc. (" Aralez " or the " Company ") announced today that it and certain of its affiliates will seek court approval for the sale of its VIMOVO ®  royalties and Canadian operations to Nuvo Pharmaceuticals Inc.
Toggle Summary Aralez Pharmaceuticals Enters Into Definitive "Stalking Horse" Purchase Agreements For Substantially All Assets
Transactions valued at an aggregate of U.S. $240 million MISSISSAUGA, Ontario, Sept. 19, 2018 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (" Aralez " or the " Company ") announced today that it and certain of its affiliates have entered into purchase agreements with two separate stalking-horse
Toggle Summary Aralez Pharmaceuticals To Enter Into Purchase Agreements To Sell Substantially All Assets
Transactions to be valued at an aggregate of U.S. $250 million Commences Voluntary Proceedings under CCAA in Canada and Chapter 11 in the United States Company to Continue Operating Business and Serving Customers As Usual MISSISSAUGA, Ontario , Aug. 10, 2018 /CNW/ --  Aralez Pharmaceuticals Inc.
Toggle Summary Aralez Enters Into Amendment To Second Amended And Restated Facility Agreement
MISSISSAUGA, Ontario , June 29, 2018 /PRNewswire/ --  Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) (" Aralez " or the " Company ") today announced that, in connection with its review of strategic alternatives, it entered into an Amendment (the " Amendment ") to that certain Second Amended
Toggle Summary Aralez Announces Voting Results From 2018 Annual Meeting Of Shareholders
MISSISSAUGA, Ontario , June 29, 2018 /PRNewswire/ --  Aralez Pharmaceuticals Inc.  (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company") today announced the results of the matters voted upon at the Company's 2018 annual meeting (the "Meeting") of the shareholders of the Company (the "Shareholders")
Toggle Summary Aralez Announces First Quarter 2018 Financial Results
-1Q 2018 Net Revenues Increased to $38.1 Million Versus $26.0 Million in 1Q 2017- MISSISSAUGA, Ontario , May 8, 2018 /PRNewswire/ --  Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) (" Aralez " or the " Company ") today announced financial results for the first quarter ending March 31, 2018 .
Toggle Summary Aralez Announces New Strategic Direction
-Focus on Canadian Operations, supported by Toprol-XL® Franchise Revenues and Vimovo® Royalties- -Discontinuation of U.S. Commercial Operations, with Significant Reductions in Operating Expenses- -Actively Exploring Strategic Alternatives for Business- MISSISSAUGA, Ontario , May 8, 2018
Toggle Summary Aralez To Announce First Quarter 2018 Results On May 8, 2018
-Executive Management to Host Conference Call on May 8, 2018 at 8:00 a.m. ET - MISSISSAUGA, Ontario , April 27, 2018 /CNW/ --  Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) today announced that it will report its first quarter 2018 financial results on Tuesday, May 8, 2018 , before the
Toggle Summary Aralez Announces Fourth Quarter and Full-Year 2017 Financial Results
-4Q 2017 Net Revenues Increased to $28.0 Million Versus $20.0 Million in the 4Q 2016- -Full-Year Net Revenues Increased to $105.9 Million Versus $54.3 Million in Full-Year 2016- -Provides 2018 Full-Year Financial Guidance- MISSISSAUGA, Ontario , March 13, 2018 /PRNewswire/ -- Aralez Pharmaceuticals
Toggle Summary Aralez To Announce Fourth Quarter And Full-Year 2017 Results On March 13, 2018
-Executive Management to Host Conference Call on March 13, 2018 at 8:30 a.m. ET - MISSISSAUGA, Ontario , March 6, 2018 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) today announced that it will report its 2017 fourth quarter and full-year financial results on Tuesday, March

Copyright West LLC. Minimum 15 minutes delayed.